In 2020,
endometrial cancer continues to be the most common gynecologic
malignancy in the United States. The majority of
endometrial cancer is low grade, and nearly 1 of every 8 low-grade
endometrial cancer diagnoses occurs in women younger than 50 years with early-stage disease. The incidence of early-stage, low-grade
endometrial cancer is increasing particularly among women in their 30s. Women with early-stage, low-grade
endometrial cancer generally have a favorable prognosis, and
hysterectomy-based surgical treatment alone can often be curative. In young women with
endometrial cancer, consideration of ovarian conservation is especially relevant to avoid both the short-term and long-term sequelae of surgical menopause including menopausal symptoms,
cardiovascular disease,
metabolic disease, and
osteoporosis. Although disadvantages of ovarian conservation include failure to remove ovarian
micrometastasis (0.4%-0.8%), gross ovarian metastatic disease (4.2%), or synchronous
ovarian cancer (3%-5%) at the time of surgery and the risk of future potential metachronous
ovarian cancer (1.2%), ovarian conservation is not negatively associated with
endometrial cancer-related or all-cause mortality in young women with early-stage, low-grade
endometrial cancer. Despite this, utilization of ovarian conservation for young women with early-stage, low-grade
endometrial cancer remains modest with only a gradual increase in uptake in the United States. We propose a framework and strategic approach to identify young women with early-stage, low-grade
endometrial cancer who may be candidates for ovarian conservation. This evidence-based schema consists of a 2-step assessment at both the preoperative and intraoperative stages that can be universally integrated into practice.